Patents Assigned to Defensin Therapeutics ApS
  • TREATMENT OF LIVER, BILIARY TRACT AND PANCREATIC DISORDERS
    Publication number: 20190192626
    Abstract: The present invention relates to methods for treatment or prevention of liver, biliary tract, and pancreatic disorders by administering one or more defensins. Included within the scope of the disclosure is also treatment of certain metabolic disorders.
    Type: Application
    Filed: April 28, 2017
    Publication date: June 27, 2019
    Applicant: DEFENSIN THERAPEUTICS APS
    Inventors: Peter Nordkild, Soren Kjaerulff
  • Oral treatment of inflammatory bowel disease
    Patent number: 9833495
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 5, 2017
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Treatment of inflammatory bowel diseases with mammal beta defensins
    Patent number: 9279010
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 8, 2016
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Oral treatment of inflammatory bowel disease
    Patent number: 9217021
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: December 22, 2015
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Treatment of inflammatory bowel diseases with mammal beta defensins
    Patent number: 8802621
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 12, 2014
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Treatment of Inflammatory Bowel Diseases with Mammal Beta Defensins
    Publication number: 20140135258
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 15, 2014
    Applicant: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen